Search research articles
Contact Us
Filters
Showing results (21-30 of 49) with videos related to
Page
of 5
Sort By:
The Eurasian Journal of Medicine
|
May 16, 2025
Impact of Cribriform Pattern on Progression-Free Survival After Radical Prostatectomy in Gleason Score 8-10 Prostate Cancer
Tyler Walburn, Yetkin Tuaç, Çağdaş Aktan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 8, 2019
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level
Vinayak Muralidhar, Paul L Nguyen, Brandon A Mahal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 13, 2026
Four-year Feasibility and Safety Results of a Phase I/II Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART) for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue Metastases
Thomas P Howard, Tyler Walburn, Grant Benham, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 6, 2022
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
Jennifer R Bellon, Nabihah Tayob, David D Yang, et al.
Brachytherapy
|
January 15, 2019
A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer
Martin T King, David D Yang, Vinayak Muralidhar, et al.
International Journal of Molecular Sciences
|
August 29, 2024
Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer
Mutlay Sayan, Yetkin Tuac, Mahmut Akgul, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 22, 2022
Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Abdominopelvic Oligometastases
David D Yang, Victoria S Brennan, Elizabeth Huynh, et al.
Urologic Oncology
|
December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer
Martin T King, Ming-Hui Chen, Brian J Moran, et al.
Brachytherapy
|
January 15, 2019
Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy
Martin T King, Paul L Nguyen, Ninjin Boldbaatar, et al.
Cancer
|
August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer
David D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 49) with videos related to
Sort By:
Page
of 5
The Eurasian Journal of Medicine
|
May 16, 2025
Impact of Cribriform Pattern on Progression-Free Survival After Radical Prostatectomy in Gleason Score 8-10 Prostate Cancer
Tyler Walburn, Yetkin Tuaç, Çağdaş Aktan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 8, 2019
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level
Vinayak Muralidhar, Paul L Nguyen, Brandon A Mahal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 13, 2026
Four-year Feasibility and Safety Results of a Phase I/II Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART) for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue Metastases
Thomas P Howard, Tyler Walburn, Grant Benham, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 6, 2022
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
Jennifer R Bellon, Nabihah Tayob, David D Yang, et al.
Brachytherapy
|
January 15, 2019
A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer
Martin T King, David D Yang, Vinayak Muralidhar, et al.
International Journal of Molecular Sciences
|
August 29, 2024
Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer
Mutlay Sayan, Yetkin Tuac, Mahmut Akgul, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 22, 2022
Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Abdominopelvic Oligometastases
David D Yang, Victoria S Brennan, Elizabeth Huynh, et al.
Urologic Oncology
|
December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer
Martin T King, Ming-Hui Chen, Brian J Moran, et al.
Brachytherapy
|
January 15, 2019
Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy
Martin T King, Paul L Nguyen, Ninjin Boldbaatar, et al.
Cancer
|
August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer
David D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Page
of 5